We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

Vertex Pharmaceuticals received a boost with Canada's approval of ALYFTREK for cystic fibrosis. This approval boosts sentiment. The stock saw a 7% rise over the past month amid broader market optimism ...

Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

The NHS will offer a once-daily triple therapy for cystic fibrosis to hundreds more patients, including those with rare ...

In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to ...

Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

Key Points Alibaba is a Chinese AI stock that's dirt cheap. Meta Platforms is making a huge bet on AI that should pay off ...

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference ...

A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...